Biohaven .(BHVN) - 2024 Q4 - Annual Results

Exhibit 99.1 Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results • Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Prescription Drug User Fee Act (PDUFA) date in 3Q 2025. • Cash, cash equivalents, marketable securities and restricted cash as of December 31, 2024 totaled approximately $489 million. • Reported posi ...